People with severe symptoms of chronic graft versus host disease (GvHD) often need to use multiple treatments to manage their condition. In recent years, a new class of medicines known as kinase ...
On Wednesday, the FDA approved Mesoblast Limited’s (NASDAQ:MESO) Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is the only MSC therapy approved in the ...
News-Medical.Net on MSN
Study provides a new paradigm for managing transplant‑related immune complications
Acute graft-versus-host disease (aGVHD) is one of the most serious complications after allogeneic hematopoietic stem cell ...
The MarketWatch News Department was not involved in the creation of this content. Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft ...
An oncology pharmacist shares how a treatment takes a different approach to treating chronic graft-versus-host disease (GVHD) ...
Xervyteg demonstrated a 62% GI overall response rate at day 28, significantly exceeding historical controls, with durable responses and survival benefits over one year. The safety profile was ...
Hematopoietic cell transplantation (HCT), also known as bone marrow transplantation, is a critical treatment for blood cancers such as leukemia, lymphoma, and myeloma, as well as certain genetic and ...
Bone marrow, or hematopoietic stem cell, transplantation (HCT) is frequently used to treat patients with leukemia by replacing the diseased bone marrow with healthy bone marrow from a donor. Yet, a ...
The Graft Versus Host Disease (GvHD) market across the seven major markets (7MM) is anticipated to witness substantial ...
Symptoms of graft-versus-host disease (GVHD), a complication of allogeneic hematopoietic stem cell transplant, can be mild to life threatening. Symptoms may affect your skin, gastrointestinal tract, ...
Graft-versus-host disease (GVHD) following liver transplantation remains a rare but devastating complication, characterised by donor immunocompetent cells initiating an immune attack against host ...
Skin, gastrointestinal, and liver symptoms are common manifestations of graft-versus-host disease (GVHD). The potentially life threatening complication is from allogeneic hematopoietic stem cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback